Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant

Anebulo Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.20

Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.
Cash $6.6M at Dec 31, 2023; secured $10M credit facility from existing investors.
Selonabant (ANEB-001) generic name adopted; IV formulation in development.
Targeting Phase 3 study start in H1 2024; new CEO Richie Cunningham and board member Bimal Shah.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anebulo Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m, EPS $(0.11) per share.

Period: the three months ended December 31, 2023
Net income: Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m
EPS: $(0.11) per share
Result: reported results

Exact text from the filing

Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-006087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.